Protagenic Therapeutics Stock Price, News & Analysis (OTCMKTS:PTIX)

$1.76 0.00 (0.00 %)
(As of 02/25/2018 04:00 PM ET)
Previous Close$1.76
Today's RangeN/A
52-Week Range$1.06 - $5.00
Volume1 shs
Average Volume2 shs
Market Capitalization$20.52 million
P/E RatioN/A
Dividend YieldN/A

About Protagenic Therapeutics (OTCMKTS:PTIX)

Protagenic Therapeutics, Inc., formerly Atrinsic, Inc., is a development-stage company. The Company is a biotechnology company that specializes in the discovery and development of therapeutics to treat central nervous system (CNS) disorders. The Company provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-base, brain active therapeutics. The Company has developed a portfolio of neuropeptides that are in various stages of development and preclinical evaluation for the treatment of various mood disorders. These neuropeptides are called PT00114, PT00121, PT00211, PT00311 and PT00411. As of September 30, 2016, the Company has not generated any revenue.

Receive PTIX News and Ratings via Email

Sign-up to receive the latest news and ratings for PTIX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Networking & Communication Devices


Debt-to-Equity RatioN/A
Current Ratio4.17%
Quick Ratio4.17%


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.24 per share
Price / Book7.33


Trailing EPSN/A
Net Income$-2,270,000.00
Net MarginsN/A
Return on Equity-104.22%
Return on Assets-80.68%


Outstanding Shares10,260,000

Protagenic Therapeutics (OTCMKTS:PTIX) Frequently Asked Questions

What is Protagenic Therapeutics' stock symbol?

Protagenic Therapeutics trades on the OTCMKTS under the ticker symbol "PTIX."

How were Protagenic Therapeutics' earnings last quarter?

Protagenic Therapeutics Inc (OTCMKTS:PTIX) released its quarterly earnings results on Monday, May, 15th. The biotechnology company reported ($0.06) EPS for the quarter. View Protagenic Therapeutics' Earnings History.

When will Protagenic Therapeutics make its next earnings announcement?

Protagenic Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, April, 17th 2018. View Earnings Estimates for Protagenic Therapeutics.

Who are some of Protagenic Therapeutics' key competitors?

Who are Protagenic Therapeutics' key executives?

Protagenic Therapeutics' management team includes the folowing people:

  • Garo H. Armen Ph.D., Chairman of the Board (Age 64)
  • Alexander K. J. Arrow M.D., Acting Chief Financial Officer (Age 47)
  • Joshua N. Silverman, Director (Age 46)
  • Robert Burton Stein, Director (Age 66)
  • Khalil Z. Barrage, Independent Director (Age 51)
  • Brian Corvese, Independent Director

How do I buy Protagenic Therapeutics stock?

Shares of Protagenic Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Protagenic Therapeutics' stock price today?

One share of Protagenic Therapeutics stock can currently be purchased for approximately $1.76.

How big of a company is Protagenic Therapeutics?

Protagenic Therapeutics has a market capitalization of $20.52 million. Protagenic Therapeutics employs 3 workers across the globe.

How can I contact Protagenic Therapeutics?

Protagenic Therapeutics' mailing address is 149 FIFTH AVENUE SUITE 500, NEW YORK NY, 10010. The biotechnology company can be reached via phone at 212-994-8200 or via email at [email protected]

MarketBeat Community Rating for Protagenic Therapeutics (PTIX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  28 (Vote Outperform)
Underperform Votes:  32 (Vote Underperform)
Total Votes:  60
MarketBeat's community ratings are surveys of what our community members think about Protagenic Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Protagenic Therapeutics (OTCMKTS:PTIX) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Protagenic Therapeutics (OTCMKTS:PTIX) Earnings History and Estimates Chart

Earnings by Quarter for Protagenic Therapeutics (OTCMKTS:PTIX)

Protagenic Therapeutics (OTCMKTS PTIX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017Q3 2017($0.04)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.04)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.06)ViewN/AView Earnings Details
11/17/2016Q3 2016($0.06)ViewN/AView Earnings Details
8/15/2016Q2 2016($14.93)ViewN/AView Earnings Details
11/7/2013Q313$0.07$4.70 million$7.30 millionViewN/AView Earnings Details
8/8/2013Q2 2013$0.06$5.00 million$7.10 millionViewN/AView Earnings Details
11/8/2012Q312($0.12)$9.00 million$4.70 millionViewN/AView Earnings Details
11/14/2011Q3 2011($7,544.84)ViewN/AView Earnings Details
8/15/2011Q2 2011($15,058.75)ViewN/AView Earnings Details
5/16/2011Q1 2011($8,627.09)ViewN/AView Earnings Details
3/31/2011Q4 2010($8,348.80)ViewN/AView Earnings Details
11/15/2010Q3 2010($10,760.67)ViewN/AView Earnings Details
8/16/2010Q2 2010($13,605.44)ViewN/AView Earnings Details
5/11/2010Q1 2010($9,894.87)ViewN/AView Earnings Details
3/30/2010Q4 2009($19,789.73)ViewN/AView Earnings Details
11/11/2009Q3 2009($7,173.78)ViewN/AView Earnings Details
8/14/2009Q2 2009($5,936.92)ViewN/AView Earnings Details
5/12/2009Q1 2009($3,525.05)ViewN/AView Earnings Details
3/26/2009Q4 2008($5,071.12)ViewN/AView Earnings Details
8/14/2008Q2 2008$4,329.00ViewN/AView Earnings Details
5/15/2008Q1 2008($865.80)ViewN/AView Earnings Details
3/27/2008Q4 2007($4,823.75)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Protagenic Therapeutics (OTCMKTS:PTIX) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Protagenic Therapeutics (OTCMKTS:PTIX)

No dividend announcements for this company have been tracked by

Insider Trades

Protagenic Therapeutics (OTCMKTS PTIX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 42.00%
Insider Trades by Quarter for Protagenic Therapeutics (OTCMKTS:PTIX)

Protagenic Therapeutics (OTCMKTS PTIX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/28/2013Quaker Capital Management CorpMajor ShareholderSell100,000$1.25$125,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Protagenic Therapeutics (OTCMKTS PTIX) News Headlines

No headlines for this company have been tracked by

SEC Filings

Protagenic Therapeutics (OTCMKTS:PTIX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Protagenic Therapeutics (OTCMKTS:PTIX) Income Statement, Balance Sheet and Cash Flow Statement


Protagenic Therapeutics (OTCMKTS PTIX) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.